

# B G Feagan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5704806/publications.pdf>

Version: 2024-02-01

369  
papers

60,728  
citations

1614

105  
h-index

962

238  
g-index

446  
all docs

446  
docs citations

446  
times ranked

20608  
citing authors

#	ARTICLE	IF	CITATIONS
1	Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. <i>Lancet</i> , The, 2002, 359, 1541-1549.	13.7	3,835
2	Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2005, 353, 2462-2476.	27.0	3,500
3	Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2013, 369, 699-710.	27.0	2,114
4	Infliximab Maintenance Therapy for Fistulizing Crohn's Disease. <i>New England Journal of Medicine</i> , 2004, 350, 876-885.	27.0	2,026
5	Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease. <i>New England Journal of Medicine</i> , 2013, 369, 711-721.	27.0	2,001
6	Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. <i>American Journal of Gastroenterology</i> , 2015, 110, 1324-1338.	0.4	1,425
7	Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. <i>New England Journal of Medicine</i> , 2016, 375, 1946-1960.	27.0	1,316
8	Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. <i>Gut</i> , 2012, 61, 1693-1700.	12.1	1,295
9	Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2017, 376, 1723-1736.	27.0	1,232
10	Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. <i>Lancet</i> , The, 2008, 371, 660-667.	13.7	1,135
11	Certolizumab Pegol for the Treatment of Crohn's Disease. <i>New England Journal of Medicine</i> , 2007, 357, 228-238.	27.0	1,100
12	Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease. <i>New England Journal of Medicine</i> , 2012, 367, 1519-1528.	27.0	984
13	Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. <i>Gastroenterology</i> , 2004, 126, 402-413.	1.3	929
14	Methotrexate for the Treatment of Crohn's Disease. <i>New England Journal of Medicine</i> , 1995, 332, 292-297.	27.0	920
15	A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis. <i>Gastroenterology</i> , 2007, 132, 763-786.	1.3	917
16	Natalizumab Induction and Maintenance Therapy for Crohn's Disease. <i>New England Journal of Medicine</i> , 2005, 353, 1912-1925.	27.0	880
17	Serious Infections and Mortality in Association With Therapies for Crohn's Disease: TREAT Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 621-630.	4.4	831
18	Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis. <i>Gastroenterology</i> , 2011, 141, 1194-1201.	1.3	792

#	ARTICLE	IF	CITATIONS
19	Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis. <i>Gastroenterology</i> , 2014, 146, 85-95.	1.3	753
20	Treatment of Ulcerative Colitis with a Humanized Antibody to the $\alpha_4\beta_7$ Integrin. <i>New England Journal of Medicine</i> , 2005, 352, 2499-2507.	27.0	736
21	A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease. <i>Gastroenterology</i> , 2008, 135, 1130-1141.	1.3	709
22	A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease. <i>New England Journal of Medicine</i> , 2000, 342, 1627-1632.	27.0	704
23	Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. <i>Gastroenterology</i> , 1994, 106, 287-296.	1.3	688
24	Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT <sub>UC</sub> Registry. <i>American Journal of Gastroenterology</i> , 2012, 107, 1409-1422.	0.4	652
25	The safety of vedolizumab for ulcerative colitis and Crohn's disease. <i>Gut</i> , 2017, 66, 839-851.	12.1	630
26	Effects of Vedolizumab Induction Therapy for Patients With Crohn's Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed. <i>Gastroenterology</i> , 2014, 147, 618-627.e3.	1.3	607
27	Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis. <i>Gastroenterology</i> , 2014, 146, 96-109.e1.	1.3	605
28	A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. <i>Gastroenterology</i> , 2002, 122, 512-530.	1.3	598
29	Natalizumab for the Treatment of Active Crohn's Disease: Results of the ENCORE Trial. <i>Gastroenterology</i> , 2007, 132, 1672-1683.	1.3	586
30	Oral Budesonide for Active Crohn's Disease. <i>New England Journal of Medicine</i> , 1994, 331, 836-841.	27.0	531
31	Development of the Crohn's disease digestive damage score, the Lönnemann score. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1415-1422.	1.9	496
32	Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. <i>Gastroenterology</i> , 2000, 119, 1473-1482.	1.3	490
33	C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2015, 110, 802-819.	0.4	465
34	Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). <i>Gut</i> , 2012, 61, 535-542.	12.1	463
35	Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab. <i>Gastroenterology</i> , 2009, 137, 1250-1260.	1.3	440
36	Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 635-646.	4.7	432

#	ARTICLE	IF	CITATIONS
37	Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. <i>Lancet, The</i> , 2014, 384, 309-318.	13.7	421
38	Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1218-1224.	4.4	372
39	Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. <i>Lancet, The</i> , 2017, 389, 1699-1709.	13.7	364
40	Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2016, 374, 1754-1762.	27.0	361
41	Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity. <i>Gastroenterology</i> , 2013, 145, 987-995.	1.3	354
42	Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. <i>Lancet, The</i> , 2015, 386, 1825-1834.	13.7	354
43	Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. <i>Gastroenterology</i> , 1999, 117, 49-57.	1.3	326
44	Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus. <i>Gastroenterology</i> , 2015, 148, 1035-1058.e3.	1.3	323
45	SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 489-501.e26.	1.0	316
46	Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 348-354.e17.	4.4	309
47	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 1599-1607.	0.4	300
48	Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2014, 146, 681-688.e1.	1.3	294
49	Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. <i>Gastroenterology</i> , 1996, 110, 45-51.	1.3	284
50	Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the $\alpha_4\beta_7$ Integrin. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1370-1377.	4.4	283
51	Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2014, 147, 1296-1307.e5.	1.3	280
52	Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. <i>Gut</i> , 2017, 66, 1049-1059.	12.1	274
53	Development and validation of a histological index for UC. <i>Gut</i> , 2017, 66, 50-58.	12.1	264
54	Low-Dose Cyclosporine for the Treatment of Crohn's Disease. <i>New England Journal of Medicine</i> , 1994, 330, 1846-1851.	27.0	256

#	ARTICLE	IF	CITATIONS
55	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. <i>Gastroenterology</i> , 2016, 150, 1568-1578.	1.3	251
56	An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial. <i>Gastroenterology</i> , 2001, 120, 1330-1338.	1.3	250
57	Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2021, 385, 1280-1291.	27.0	243
58	Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1042-1050.e2.	4.4	240
59	The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. <i>Gut</i> , 2015, 64, 1539-1545.	12.1	239
60	Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. <i>Gastroenterology</i> , 1999, 117, 527-535.	1.3	236
61	Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. <i>Gastroenterology</i> , 2017, 153, 77-86.e6.	1.3	232
62	Inflammatory Bowel Disease: A Canadian Burden of Illness Review. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2012, 26, 811-817.	1.7	229
63	Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 188-202.	3.7	210
64	Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1470-1479.	1.9	205
65	Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2016, 4, CD000543.	2.8	202
66	Factors Associated with the Development of Intestinal Strictures or Obstructions in Patients with Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2006, 101, 1030-1038.	0.4	200
67	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2016, , CD000544.	2.8	197
68	The Role of Centralized Reading of Endoscopy in a Randomized Controlled Trial of Mesalamine for Ulcerative Colitis. <i>Gastroenterology</i> , 2013, 145, 149-157.e2.	1.3	196
69	Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1079-1087.	4.4	194
70	Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2021, 397, 2372-2384.	13.7	194
71	Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. <i>Gastroenterology</i> , 2020, 158, 2123-2138.e8.	1.3	189
72	Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 233-242.	1.9	187

#	ARTICLE	IF	CITATIONS
73	Global burden of inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 2020, 5, 2-3.	8.1	187
74	Converging Goals of Treatment of Inflammatory Bowel Disease From Clinical Trials and Practice. Gastroenterology, 2015, 148, 37-51.e1.	1.3	185
75	Annual cost of care for Crohn's disease: a payor perspective. American Journal of Gastroenterology, 2000, 95, 1955-1960.	0.4	179
76	Assessment of Crohn's disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review. Gut, 2019, 68, 1115-1126.	12.1	178
77	Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology, 2018, 154, 1660-1671.	1.3	175
78	A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab. Clinical Gastroenterology and Hepatology, 2013, 11, 654-666.	4.4	168
79	Oral p38 Mitogen-Activated Protein Kinase Inhibition With BIRB 796 for Active Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Gastroenterology and Hepatology, 2006, 4, 325-334.	4.4	165
80	Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clinical Gastroenterology and Hepatology, 2017, 15, 229-239.e5.	4.4	164
81	Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT <sup>2</sup> Registry. American Journal of Gastroenterology, 2014, 109, 212-223.	0.4	160
82	A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity. Alimentary Pharmacology and Therapeutics, 2015, 41, 77-86.	3.7	160
83	The Effects of Infliximab Therapy on Health-Related Quality of Life in Ulcerative Colitis Patients. American Journal of Gastroenterology, 2007, 102, 794-802.	0.4	157
84	An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2018, 48, 347-357.	3.7	157
85	IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. Gut, 2016, 65, 1447-1455.	12.1	155
86	IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. Journal of Crohn's and Colitis, 2020, 14, 23-32.	1.3	149
87	Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut, 2015, 64, 77-83.	12.1	145
88	Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. Gastroenterology, 2019, 157, 1007-1018.e7.	1.3	145
89	CDP571, a humanised monoclonal antibody to tumour necrosis factor $\alpha$ , for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut, 2004, 53, 1485-1493.	12.1	144
90	Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Annals of the Rheumatic Diseases, 2019, 78, 473-479.	0.9	143

#	ARTICLE	IF	CITATIONS
91	Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 670-678.e3.	4.4	142
92	Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus Statements. <i>American Journal of Gastroenterology</i> , 2012, 107, 179-194.	0.4	142
93	Long-term Efficacy of Vedolizumab for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw176.	1.3	141
94	Long-term Efficacy of Vedolizumab for Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw177.	1.3	140
95	The challenge of indication extrapolation for infliximab biosimilars. <i>Biologics</i> , 2014, 42, 177-183.	1.4	138
96	Association Between Response to Etrolizumab and Expression of Integrin $\alpha$ E and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 477-487.e9.	1.3	133
97	Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. <i>Gut</i> , 2006, 55, 1568-1574.	12.1	131
98	Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 921-929.	1.3	130
99	Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 158, 537-549.e10.	1.3	130
100	Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 65-77.	3.7	128
101	Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 671-680.	8.1	126
102	Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. <i>Lancet</i> , 2022, 399, 2015-2030.	13.7	126
103	Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 155, 1045-1058.	1.3	125
104	A Randomized Study Comparing a Patient-Directed Hypertension Management Strategy With Usual Office-Based Care. <i>American Journal of Hypertension</i> , 1997, 10, 58-67.	2.0	121
105	Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2031-2045.e11.	4.4	121
106	Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. <i>Gut</i> , 2017, 66, 588-596.	12.1	117
107	Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1200-1210.	3.7	115
108	Methotrexate for induction of remission in refractory Crohn's disease. <i>The Cochrane Library</i> , 2015, CD003459.	2.8	113



#	ARTICLE	IF	CITATIONS
109	Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2012, 18, 349-358.	1.9	110
110	Development of an index to define overall disease severity in IBD. Gut, 2018, 67, 244-254.	12.1	108
111	Systematic review: the effectiveness of budesonide therapy for Crohn's disease. Alimentary Pharmacology and Therapeutics, 2002, 16, 1509-1517.	3.7	107
112	Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet, The, 2022, 399, 2031-2046.	13.7	105
113	Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease. Alimentary Pharmacology and Therapeutics, 2009, 29, 1032-1041.	3.7	104
114	Histologic Evaluation of Ulcerative Colitis. Inflammatory Bowel Diseases, 2014, 20, 564-575.	1.9	102
115	Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease—an International, Cross-disciplinary Consensus. Journal of Crohn's and Colitis, 2018, 12, 408-418.	1.3	102
116	Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2018, 16, 1879-1892.	4.4	101
117	Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis. Gastroenterology, 2020, 159, 1262-1275.e7.	1.3	101
118	Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies. Journal of Crohn's and Colitis, 2017, 11, 35-46.	1.3	100
119	Long-term safety of vedolizumab for inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 1353-1365.	3.7	97
120	Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2013, 38, 447-459.	3.7	96
121	Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. Journal of Crohn's and Colitis, 2018, 12, 1158-1169.	1.3	95
122	Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. The Lancet Gastroenterology and Hepatology, 2020, 5, 819-828.	8.1	95
123	Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. Clinical Gastroenterology and Hepatology, 2022, 20, 578-590.e4.	4.4	94
124	Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process. American Journal of Gastroenterology, 2012, 107, 1770-1776.	0.4	93
125	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. Gastroenterology, 2018, 155, 687-695.e10.	1.3	93
126	A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Alimentary Pharmacology and Therapeutics, 2014, 39, 1126-1135.	3.7	90



#	ARTICLE	IF	CITATIONS
127	Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. <i>Gastroenterology</i> , 2022, 162, 1650-1664.e8.	1.3	88
128	A Multicenter, Randomized, Double-Blind Trial of Everolimus Versus Azathioprine and Placebo to Maintain Steroid-Induced Remission in Patients With Moderate-to-Severe Active Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2008, 103, 2284-2292.	0.4	87
129	Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Current State and Future Perspectives. <i>Current Gastroenterology Reports</i> , 2014, 16, 378.	2.5	86
130	Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1170-1181.	3.7	86
131	Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 674-688.	3.7	84
132	An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC). <i>Gastroenterology</i> , 2000, 118, A874.	1.3	81
133	Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest. <i>Gastroenterology</i> , 2017, 152, S1308-S1309.	1.3	77
134	Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 621-626.	1.3	77
135	The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 105-119.	1.3	76
136	Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 130-138.e7.	4.4	76
137	Assessment of mucosal healing in inflammatory bowel disease: review. <i>Gastrointestinal Endoscopy</i> , 2015, 82, 246-255.	1.0	74
138	Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. <i>Gut</i> , 2016, 65, 1119-1125.	12.1	74
139	Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1691-1699.	1.9	73
140	Briakinumab for Treatment of Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	1.9	67
141	Reproducibility of histological assessments of disease activity in UC. <i>Gut</i> , 2015, 64, 1765-1773.	12.1	66
142	A phase II study of laquinimod in Crohn's disease. <i>Gut</i> , 2015, 64, 1227-1235.	12.1	66
143	Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 5-23.	3.7	66
144	Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 994-1007.	1.9	66

#	ARTICLE	IF	CITATIONS
145	Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. Current Treatment Options in Gastroenterology, 2018, 16, 129-146.	0.8	64
146	Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Alimentary Pharmacology and Therapeutics, 2019, 49, 31-40.	3.7	64
147	Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2015, 42, 504-514.	3.7	63
148	Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2018, 63, 825-833.	2.3	62
149	Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. Journal of Crohn's and Colitis, 2019, 13, 50-57.	1.3	61
150	Vedolizumab for Induction and Maintenance of Remission in Ulcerative Colitis. Inflammatory Bowel Diseases, 2015, 21, 1151-1159.	1.9	60
151	Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease. Gastroenterology, 2018, 154, 61-64.e6.	1.3	59
152	Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. Journal of Crohn's and Colitis, 2021, 15, 1120-1129.	1.3	59
153	Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease. Gastroenterology, 2019, 157, 1233-1244.e5.	1.3	58
154	Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease. BioDrugs, 2020, 34, 713-721.	4.6	58
155	An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. Gastroenterology, 2021, 160, 2291-2302.	1.3	57
156	A Systematic Review of Measurement of Endoscopic Disease Activity and Mucosal Healing in Crohn's Disease. Inflammatory Bowel Diseases, 2014, 20, 1850-1861.	1.9	56
157	Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study. American Journal of Gastroenterology, 2020, 115, 738-745.	0.4	56
158	Are There Any Differences in the Efficacy and Safety of Different Formulations of Oral 5-ASA Used for Induction and Maintenance of Remission in Ulcerative Colitis? Evidence from Cochrane Reviews. Inflammatory Bowel Diseases, 2013, 19, 1.	1.9	55
159	Cost-effectiveness analysis of arthroscopic surgery compared with non-operative management for osteoarthritis of the knee. BMJ Open, 2016, 6, e009949.	1.9	54
160	Review article: Drug development in inflammatory bowel disease: budesonide—a model of targeted therapy. Alimentary Pharmacology and Therapeutics, 1997, 11, 98-108.	3.7	53
161	Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2016, 44, 157-169.	3.7	53
162	The development of a magnetic resonance imaging index for fistulising Crohn's disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 516-528.	3.7	53

#	ARTICLE	IF	CITATIONS
163	Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 1019-1031.e7.	1.3	52
164	Reliability of histologic assessment in patients with eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 940-950.	3.7	51
165	Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. <i>American Journal of Gastroenterology</i> , 2018, 113, 1678-1688.	0.4	51
166	Innovations in Oral Therapies for Inflammatory Bowel Disease. <i>Drugs</i> , 2019, 79, 1321-1335.	10.9	51
167	Toward a Personalized Medicine Approach to the Management of Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2014, 109, 994-1004.	0.4	50
168	The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 607-616.	1.3	50
169	Histopathology Scoring Systems of Stenosis Associated With Small Bowel Crohn's Disease: A Systematic Review. <i>Gastroenterology</i> , 2020, 158, 137-150.e1.	1.3	50
170	Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. <i>Gut</i> , 2009, 58, 1354-1362.	12.1	49
171	Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1158-1169.	3.7	49
172	Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 118-127.	8.1	49
173	Health-Related Quality of Life During Natalizumab Maintenance Therapy for Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2007, 102, 2737-2746.	0.4	48
174	Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2022, 162, 26-31.	1.3	48
175	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2952-2961.e8.	4.4	48
176	Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 440-449.	1.9	47
177	5-ASA therapy for active Crohn's disease: Old friends, old data, and a new conclusion. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 376-378.	4.4	46
178	Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. <i>Gut</i> , 2019, 68, 1162-1168.	12.1	45
179	Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 128-140.	8.1	45
180	Therapeutics and inflammatory bowel disease: A guide to the interpretation of randomized controlled trials. <i>Gastroenterology</i> , 1996, 110, 275-283.	1.3	44

#	ARTICLE	IF	CITATIONS
181	Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease. Journal of Crohn's and Colitis, 2018, 12, 167-177.	1.3	44
182	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clinical Gastroenterology and Hepatology, 2018, 16, 637-647.e13.	4.4	44
183	CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology and Therapeutics, 2006, 23, 617-628.	3.7	43
184	Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. Alimentary Pharmacology and Therapeutics, 2017, 45, 1058-1072.	3.7	43
185	Systematic Review: Disease Activity Indices in Eosinophilic Esophagitis. American Journal of Gastroenterology, 2017, 112, 1658-1669.	0.4	43
186	Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn's disease. Alimentary Pharmacology and Therapeutics, 2021, 53, 873-886.	3.7	43
187	Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 351-366.	17.8	43
188	Histologic scoring indices for evaluation of disease activity in ulcerative colitis. The Cochrane Library, 2017, 2017, CD011256.	2.8	42
189	Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. American Journal of Gastroenterology, 2019, 114, 733-745.	0.4	42
190	T-Cell Trafficking and Anti-Adhesion Strategies in Inflammatory Bowel Disease: Current and Future Prospects. Drugs, 2014, 74, 297-311.	10.9	41
191	Assessment of Histologic Disease Activity in Crohn's Disease. Inflammatory Bowel Diseases, 2014, 20, 2092-2103.	1.9	41
192	Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 1021-1042.	3.7	41
193	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. Clinical Gastroenterology and Hepatology, 2018, 16, 1407-1419.e22.	4.4	41
194	Clinically Meaningful Improvement in Health-Related Quality of Life in a Randomized Controlled Trial of Certolizumab Pegol Maintenance Therapy for Crohn's Disease. American Journal of Gastroenterology, 2009, 104, 1976-1983.	0.4	40
195	Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Alimentary Pharmacology and Therapeutics, 2011, 33, 541-550.	3.7	40
196	No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. American Journal of Gastroenterology, 2018, 113, 1197-1205.	0.4	40
197	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). Journal of Allergy and Clinical Immunology, 2022, 149, 659-670.	2.9	40
198	Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human) Tj ETQq0 0 0 rgBT /Overlock 10 Inflammatory Bowel Diseases, 2010, 16, 1708-1716.	1.9	39

#	ARTICLE	IF	CITATIONS
199	Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 607-618.	1.3	39
200	Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised <sc>GEMINI</sc> 1 trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 264-275.	3.7	39
201	Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2017, 112, 1584-1592.	0.4	37
202	Etolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 28-37.	8.1	37
203	566 Infliximab Concentration and Clinical Outcome in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2012, 142, S-114.	1.3	36
204	The safety of vedolizumab for the treatment of ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 501-507.	2.4	35
205	Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. <i>BMJ Open</i> , 2017, 7, e016146.	1.9	35
206	A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 373-384.	3.7	34
207	Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials. <i>Gut</i> , 2018, 67, 61-69.	12.1	34
208	Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview. <i>Drugs</i> , 2017, 77, 363-377.	10.9	33
209	Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1714-1729.e3.	4.4	33
210	Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1047-1066.	3.7	33
211	Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1578-1596.	3.7	31
212	Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 105-115.e14.	4.4	31
213	Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases. <i>Physiological Reviews</i> , 2022, 102, 605-652.	28.8	31
214	A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 553-564.	3.7	30
215	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2020, 2020, CD000544.	2.8	30
216	565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD). <i>Gastroenterology</i> , 2012, 142, S-114.	1.3	29

#	ARTICLE	IF	CITATIONS
217	Randomised non-inferiority trial: 1600Âmg versus 400Âmg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 292-302.	3.7	29
218	Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 360-369.e2.	1.0	29
219	International consensus to standardise histopathological scoring for small bowel strictures in Crohn's disease. <i>Gut</i> , 2022, 71, 479-486.	12.1	29
220	Overview of Subsequent Entry Biologics for the Management of Inflammatory Bowel Disease and Canadian Association of Gastroenterology Position Statement on Subsequent Entry Biologics. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2013, 27, 567-571.	1.7	28
221	IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101604.	2.4	28
222	Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1100-1111.	3.7	27
223	Declining hospitalisation and surgical intervention rates in patients with Crohn's disease: a population-based cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1086-1093.	3.7	27
224	Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1008-1016.	3.7	27
225	Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016). <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2500-2509.e1.	4.4	27
226	Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2001-2010.	1.3	27
227	Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	1.9	26
228	Effect of Standardised Scoring Conventions on Inter-rater Reliability in the Endoscopic Evaluation of Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1006-1014.	1.3	26
229	Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 435-445.	3.7	26
230	Systematic review: medical therapy for fibrostenosing Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1233-1246.	3.7	26
231	Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1201-1216.	1.3	25
232	The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence. <i>Advances in Therapy</i> , 2020, 37, 4491-4518.	2.9	25
233	Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 817-846.e10.	4.4	25
234	Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1188-1194.	3.7	24



#	ARTICLE	IF	CITATIONS
235	OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i042-i043.	1.3	24
236	Alicaforsen for the treatment of inflammatory bowel disease. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 991-997.	4.1	23
237	Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1760-1768.e1.	4.4	22
238	Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2020, 2020, CD000543.	2.8	22
239	Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease. <i>Drugs</i> , 2021, 81, 333-347.	10.9	22
240	Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1401-1409.	3.7	21
241	DOP058 Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S42-S43.	1.3	19
242	Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 987-997.	2.4	19
243	Efficient Early Drug Development for Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 1056-1060.	1.3	19
244	Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 246-255.	1.3	19
245	882 - Efficacy and Safety of Anti-Interleukin-23 Therapy with Mirikizumab (LY3074828) in Patients with Moderate-To-Severe Ulcerative Colitis in a Phase 2 Study. <i>Gastroenterology</i> , 2018, 154, S-1360-S-1361.	1.3	19
246	Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's disease. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 649-660.	4.1	19
247	What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101602.	2.4	19
248	Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1121-1132.e2.	4.4	18
249	An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 784-793.	3.7	18
250	Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1 $\alpha$ stabiliser, for treatment of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 401-411.	3.7	18
251	Health Canada/BIOTEC Canada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012. <i>Biologicals</i> , 2012, 40, 517-527.	1.4	17
252	Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 304-313.	1.9	17



#	ARTICLE	IF	CITATIONS
253	Benefitâ€“Risk Assessment of Vedolizumab in the Treatment of Crohnâ€™s Disease and Ulcerative Colitis. Drug Safety, 2019, 42, 617-632.	3.2	17
254	Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2020, 18, 2139-2141.e2.	4.4	17
255	The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2018, 12, 883-895.	1.3	16
256	Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. Gastroenterology, 2020, 159, 2013-2018.e7.	1.3	16
257	Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials. Clinical Gastroenterology and Hepatology, 2022, 20, 727-736.e2.	4.4	16
258	S1051 Methotrexate for the Prevention of Antibodies to Infliximab in Patients With Crohn's Disease. Gastroenterology, 2010, 138, S-167-S-168.	1.3	15
259	A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score. The Lancet Gastroenterology and Hepatology, 2019, 4, 63-70.	8.1	15
260	Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2020, 18, 424-431.e7.	4.4	15
261	Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. American Journal of Gastroenterology, 2020, 115, 885-894.	0.4	15
262	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. Hepatology, 2022, 76, 1150-1163.	7.3	15
263	Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol. Inflammatory Bowel Diseases, 2017, 23, 1047-1056.	1.9	14
264	Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderateâ€“Severe Ulcerative Colitis and Crohnâ€™s Disease. Inflammatory Bowel Diseases, 2020, 26, 515-523.	1.9	14
265	Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis. Scientific Reports, 2021, 11, 18243.	3.3	14
266	Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis. Pharmacotherapy, 2015, 35, 412-423.	2.6	13
267	Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. The Cochrane Library, 2017, 9, CD011572.	2.8	13
268	Responsiveness of a Histologic Scoring System Compared With Peak Eosinophil Count in Eosinophilic Esophagitis. American Journal of Gastroenterology, 2022, 117, 264-271.	0.4	13
269	An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. Alimentary Pharmacology and Therapeutics, 2021, 53, 1108-1117.	3.7	13
270	P-140â€“fPharmacokinetic/Pharmacodynamic Relationship and Immunogenicity of Vedolizumab in Adults with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, S80.	1.9	12

#	ARTICLE	IF	CITATIONS
271	Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicilate use in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 114-126.	3.7	12
272	Physicians's Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicilate Use in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2555-2563.	2.3	12
273	Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: <sc>ERELATE</sc> Study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 463-476.	3.7	12
274	Ozanimod Treatment for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2016, 375, e17.	27.0	11
275	OP23 The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i025-i026.	1.3	11
276	Antibiotics for induction and maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , 2017, , .	2.8	10
277	OP023 A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in moderately to severely active Crohn's disease (CD). <i>Journal of Crohn's and Colitis</i> , 2018, 12, S016-S017.	1.3	10
278	Placebo Rates in Randomized Controlled Trials of Pouchitis Therapy. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2519-2528.	2.3	10
279	OP27 Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: Final results from the Phase 2 open-label extension study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S024-S025.	1.3	10
280	Responsiveness of Magnetic Resonance Enterography Indices for Evaluation of Luminal Disease Activity in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2598-2606.	4.4	10
281	The Role of Biomarkers in Clinical Trials of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1619-1623.	1.9	9
282	Alternative and Complementary Approaches for the Treatment of Inflammatory Bowel Disease: Evidence From Cochrane Reviews. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 843-851.	1.9	9
283	Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 224-243.	1.3	9
284	Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn's Disease: Meta-Analysis of Randomised Controlled Trials. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 717-736.	1.3	9
285	Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial. <i>Intestinal Research</i> , 2023, 21, 110-125.	2.6	9
286	The Next Wave of Biological Agents for the Treatment of IBD. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1737-1743.	1.9	8
287	Briakinumab (Anti-interleukin 12/23p40, ABT874) for Treatment of Crohn's Disease (CD). <i>American Journal of Gastroenterology</i> , 2010, 105, S457-S458.	0.4	8
288	1053 Early Combined Immunosuppression for the Management of Crohn's Disease: A Community-Based Cluster Randomized Trial. <i>Gastroenterology</i> , 2014, 146, S-187.	1.3	7

#	ARTICLE	IF	CITATIONS
289	The Evolution of Treatment Paradigms in Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 661-677.	2.2	7
290	Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study. <i>Gastroenterology</i> , 2017, 152, S602.	1.3	7
291	Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 279-288.	2.1	7
292	Portal Hypertensive Bleeding. , 0, , 453-485.		7
293	Pharmacokinetic drug evaluation of budesonide in the treatment of Crohn's disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 793-801.	3.3	6
294	Adalimumab for maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , 2020, 2020, CD012877.	2.8	6
295	Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e750-e760.	4.4	6
296	Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 178-190.	3.7	6
297	Infliximab in the Treatment of Crohn's Disease. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2000, 14, 6C-6C.	1.7	5
298	P592 A phase 1, double-blind placebo-controlled single-dose study to determine the immune response to systemic and mucosal antigenic challenge in the presence of vedolizumab. <i>Journal of Crohn's and Colitis</i> , 2013, 7, S248.	1.3	5
299	Evolution of the Randomized Controlled Trial in Inflammatory Bowel Disease: Current Challenges and Future Solutions. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2155-2164.	1.9	5
300	P661 Early histological improvement demonstrated with oral ozanimod in patients with moderately to severely active Crohn's disease in the STEPSTONE trial. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S450-S450.	1.3	5
301	Early Combined Immunosuppression May Be More Effective for Reducing Complications in Isolated Colonic- vs Ileal-Dominant Crohn Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 639-646.	1.9	5
302	Ogilvie's Syndrome. , 0, , 303-309.		5
303	Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1574-1582.	3.7	5
304	Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD. <i>Current Treatment Options in Gastroenterology</i> , 2014, 12, 76-89.	0.8	4
305	Effect of Vedolizumab Treatment on Extraintestinal Manifestations in Patients with Crohn's Disease: A Gemini 2 Post hoc Analysis. <i>Gastroenterology</i> , 2017, 152, S597.	1.3	4
306	Efficacy and Safety of Open-Label Maintenance Therapy with Subcutaneous Risankizumab in Patients with Moderately-Severe Crohn's Disease. <i>Gastroenterology</i> , 2017, 152, S1310.	1.3	4

#	ARTICLE	IF	CITATIONS
307	Editorial: treating strictures in inflammatory bowel disease—authors’ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1313-1314.	3.7	4
308	Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1128-1155.	2.3	4
309	Endoscopic and Clinical Efficacy Demonstrated With Oral Ozanimod in Moderately to Severely Active Crohn’s Disease. <i>American Journal of Gastroenterology</i> , 2017, 112, S371.	0.4	4
310	A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. <i>Saudi Journal of Gastroenterology</i> , 2015, 21, 185.	1.1	4
311	Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1442-1453.	3.7	4
312	Early Combined Immunosuppression Reduces Complications in Long-standing Crohn's Disease: A Post Hoc Analysis of REACT. <i>Clinical Gastroenterology and Hepatology</i> , 2020, , .	4.4	4
313	Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 447-454.e1.	4.4	4
314	Design of Clinical Trials for Mild to Moderate Ulcerative Colitis. <i>Gastroenterology</i> , 2022, 162, 1005-1018.	1.3	4
315	Vedolizumab Induction Therapy for Patients With Crohn’s Disease and Prior Anti-TNF Antagonist Failure: A Randomized, Placebo-controlled, Double-blind, Multicenter Trial. <i>Inflammatory Bowel Diseases</i> , 2012, 18, S24-S25.	1.9	3
316	New Applications for Traditional Drugs in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2948-2957.	1.9	3
317	Vedolizumab for the treatment of inflammatory bowel diseases. <i>Clinical Investigation</i> , 2015, 5, 247-255.	0.0	3
318	Emerging Therapies for Inflammatory Bowel Diseases. <i>Digestive Diseases</i> , 2016, 34, 67-73.	1.9	3
319	Sa1937 Exposure-Response Relationship for Certolizumab Pegol During the Induction Phase in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2016, 150, S409.	1.3	3
320	Infliximab for maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , 0, , .	2.8	3
321	Evaluation of the effect of storage condition on cell extraction and flow cytometric analysis from intestinal biopsies. <i>Journal of Immunological Methods</i> , 2018, 459, 50-54.	1.4	3
322	Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 364-374.	3.7	3
323	Identifying Outcomes in Clinical Trials of Pouchitis for the Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1637-1640.	4.4	3
324	Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid?. <i>Current Treatment Options in Gastroenterology</i> , 2020, 18, 15-32.	0.8	3

#	ARTICLE	IF	CITATIONS
325	The role of imaging in determining prognosis for primary sclerosing cholangitis: A systematic review. Saudi Journal of Gastroenterology, 2019, 25, 152.	1.1	3
326	Update on Tofacitinib for Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2016, 12, 572-574.	0.1	3
327	Natalizumab reduces the rate of hospitalization in moderate to severe Crohn's Patients: Evidence from the Clinical Trial Program. Inflammatory Bowel Diseases, 2009, 15, S27.	1.9	2
328	Baseline Corticosteroid Use and Corticosteroid-Free Clinical Remission in Crohn's Disease Patients Treated With Certolizumab Pegol in the PRECISE 2 Trial. Inflammatory Bowel Diseases, 2012, 18, S23-S24.	1.9	2
329	Adalimumab for maintenance of remission in Crohn's disease. The Cochrane Library, 0, , .	2.8	2
330	Editorial: validating reliability of the eosinophilic oesophagitis histological scoring system (<sc>EOE</sc>â€‹<sc>HSS</sc>)â€‹"an important first step. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 1714-1715.	3.7	2
331	Novel Therapeutics for the Treatment of IBD: Current Status and Future Directions. Current Treatment Options in Gastroenterology, 2020, 18, 442-461.	0.8	2
332	Routine incorporation of the local read in Crohn's disease clinical trials? Not so fast. Gastrointestinal Endoscopy, 2021, 93, 183-186.	1.0	2
333	Safety and Positioning of Vedolizumab in Patients With Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2018, 14, 244-246.	0.1	2
334	Adalimumab Induction Dose Reduces Hospitalization Risk in Patients With Ulcerative Colitis During the First 8 Weeks of Therapy. Inflammatory Bowel Diseases, 2012, 18, S40-S41.	1.9	1
335	Combination therapy for the treatment of Crohn's disease. Expert Opinion on Biological Therapy, 2015, 15, 1429-1442.	3.1	1
336	Editorial: the impact of the placebo effect in Crohn's disease â€“ author's reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 1472-1472.	3.7	1
337	Controversies in Inflammatory Bowel Disease: Exploring Clinical Dilemmas Using Cochrane Reviews. Inflammatory Bowel Diseases, 2019, 25, 472-478.	1.9	1
338	Editorial: histologic normalisation in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2020, 51, 399-401.	3.7	1
339	Medical Management Following Surgical Therapy in Inflammatory Bowel Disease: Evidence from Cochrane Reviews. Inflammatory Bowel Diseases, 2021, 27, 1513-1524.	1.9	1
340	Clostridium Difficile Disease. , 0, , 285-301.		1
341	Ascites, Hepatorenal Syndrome, and Spontaneous Bacterial Peritonitis. , 0, , 487-503.		1
342	Non-Variceal Gastrointestinal Hemorrhage. , 0, , 139-159.		1

#	ARTICLE	IF	CITATIONS
343	Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2014, 10, 478-489.	0.1	1
344	Updates in Clinical, Endoscopic, and Histologic Composite and Co-primary Endpoints for Clinical Trials in Inflammatory Bowel Disease. Current Treatment Options in Gastroenterology, 2021, 19, 608.	0.8	1
345	Colorectal Cancer in Ulcerative Colitis: Surveillance. , 0, , 247-253.		1
346	Design of Clinical Trials for Mild to Moderate Crohn's Disease. Gastroenterology, 2022, , .	1.3	1
347	Gallstone Disease. , 0, , 311-320.		1
348	Liver Transplantation: Prevention and Treatment of Infection. , 0, , 573-586.		1
349	The Relationship Between Plasma Concentrations of Certolizumab Pegol and Clinical Efficacy: Results From the PRECISE 2 Trial. Inflammatory Bowel Diseases, 2012, 18, S23.	1.9	0
350	Letter: limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease - authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 40, 121-122.	3.7	0
351	Reply. Gastroenterology, 2016, 150, 1041-1042.	1.3	0
352	Editorial: aminosaliclates in Crohn's disease's prevalence, risks, costs and time to reassess? Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 489-489.	3.7	0
353	Editorial: evolving histological assessment of NASH. Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 1245-1246.	3.7	0
354	P185 A comparison of early response parameters to inform a treat-to-target approach in ulcerative colitis. Journal of Crohn's and Colitis, 2020, 14, S231-S231.	1.3	0
355	A Summary of the Meetings of the Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus. Gastroenterology, 2021, 161, 778-784.	1.3	0
356	Anti-adhesion strategies for inflammatory bowel disease. Gastroenterology and Hepatology, 2010, 6, 372-4.	0.1	0
357	Benefits, Concerns, and Future Directions of Biosimilars in Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2017, 13, 745-747.	0.1	0
358	Review of the Landmark VARSITY Trial. Gastroenterology and Hepatology, 2021, 17, 330-332.	0.1	0
359	P700 The GEM Project: Stool metabolomic profile is associated with microbiome risk score and with future onset of Crohn's disease in healthy first-degree relatives. Journal of Crohn's and Colitis, 2022, 16, i596-i597.	1.3	0
360	Pouchitis After Restorative Proctocolectomy. , 0, , 211-219.		0

#	ARTICLE	IF	CITATIONS
361	Barrett's Esophagus. , 0, , 55-68.		0
362	Liver Transplantation: Prevention and Treatment of Rejection. , 0, , 545-571.		0
363	Management of Hepatitis B and C After Liver Transplantation. , 0, , 587-601.		0
364	Esophageal Motility Disorders: Achalasia and Spastic Motor Disorders. , 0, , 69-81.		0
365	Functional Dyspepsia. , 0, , 161-168.		0
366	Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitisâ€”authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 957-958.	3.7	0
367	Development and Validation of a Digital Analysis Method to Quantify CD3-immunostained T Lymphocytes in Whole Slide Images of Crohn's Disease Biopsies. Applied Immunohistochemistry and Molecular Morphology, 2022, Publish Ahead of Print, .	1.2	0
368	Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel Disease.. Gastroenterology and Hepatology, 2022, 18, 14-27.	0.1	0
369	Comparison of the Relative Sensitivity of Clinical, Endoscopic, and Histologic Remission for Detection of Treatment Efficacy in Ulcerative Colitis Trials. Inflammatory Bowel Diseases, 0, , .	1.9	0